BioCat to Distribute SwitchGear Genomics’ LightSwitch Luciferase Assay System
Deal includes Austria, Germany, and Switzerland.
![A Wyss Institute team devised a CRISPR/Cas9-based mutation prevention system that is capable of discriminating a single-nucleotide variation (indicated here in green) in the DNA code (in blue) to readily remove newly occurring disease-associated mutations. [Meletios Verras/Getty Images]](https://www.genengnews.com/wp-content/uploads/2018/08/Nov21_2017_Getty_859573154_CRISPRCas9System_6001021125349-324x160.jpg "CRISPR Adapted to Prevent Unwanted Mutations")
CRISPR Adapted to Prevent Unwanted Mutations
Tests by Wyss Institute scientists showed how their CRISPR/Cas9 genome surveillance tool can target and cleave DNA carrying single-base substitutions and hold back the emergence of antibiotic-resistant bacteria.
FDA Lifts Clinical Hold on Cellectis CAR-T Trials
The FDA lifts the clinical hold placed in September on Cellectis' two Phase I studies of its CAR-T immunotherapy candidate UCART123 after a patient death
Roswell Park Joins Jasco to Develop Lead Agent for Cancer
PIM inhibitor JP_11646 has shown promise in preclinical studies against several solid tumors and blood cancers.
NIAID Taps NanoBio’s Adjuvant for Pandemic Influenza Vaccine
NIAID has contracted with NanoBio for access to its nanoemulsion (NE) adjuvant for the second time in a year.
Genewiz Collaboration Spree Covers Ovarian Cancer Biomarkers, Next-Gen MDx
Genewiz is collaborating with the John Theurer Cancer Center at Hackensack University Medical Center with the goal of advancing ovarian cancer biomarker discovery research.
GlycoVaxyn and Brigham and Women’s Win $3.4M to Develop S. aureus...
Second-generation product expected to provide broad protection against a range of bacterial strains.
Researchers Demonstrate Viability of Targeting Intracellular Proteins with Antibodies to Treat...
Both antibody and antigen-mediated immunotherapies led to tumor regression in mice.
Venom Goes to Bat as Novel Medical Treatment
Novel therapeutics, even when they come from unexpected places, are a welcome addition to the armamentarium of drugs available to treat diseases. Now, a...
Heroin Antibody Fares Better than Earlier Therapies That Targeted Its Metabolites
A monoclonal antibody against heroin (11D12) is effective in blocking the euphoric and lethal effects of this much-abused opioid. The current findings clarify the reasons underlying the failure of earlier attempts in developing therapeutics that targeted heroin’s metabolites. 11D12 blocks heroin’s analgesic effects and prevents heroin from slowing breathing and heart rates—the direct causes underlying heroin’s lethality. Moreover, 11D12 remains active in circulation for weeks.
